当前位置: X-MOL 学术Ophthalmology › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Success of Weekly Adalimumab in Refractory Ocular Inflammatory Disease.
Ophthalmology ( IF 13.1 ) Pub Date : 2020-04-17 , DOI: 10.1016/j.ophtha.2020.04.009
Jennifer Lee 1 , Anjum F Koreishi 1 , Katelyn B Zumpf 2 , Caroline L Minkus 1 , Debra A Goldstein 1
Affiliation  

Purpose

Evaluate the efficacy of weekly adalimumab (ADA) in patients with non-infectious ocular inflammation who failed standard every other week (EOW) dosing.

Design

Single-center, retrospective, study.

Subjects

Patients with uncontrolled inflammation on ADA EOW who were escalated to weekly dosing.

Methods

Chart review conducted at Northwestern University, January 2012 to April 2019.

Outcome: Number of treatment successes on weekly ADA at 6 and 12 months.

Results

Fourteen of 25 patients (56%) achieved disease control at 6 months; no additional failures occurred at 12 months.

Conclusion

Weekly ADA is a reasonable treatment option in patients with recalcitrant inflammation on standard dosing.



中文翻译:

每周使用阿达木单抗治疗难治性眼炎的成功率。

目的

评估每周一次阿达木单抗(ADA)在非感染性眼部炎症患者中每两周一次标准剂量(EOW)给药失败的疗效。

设计

单中心回顾性研究。

科目

ADA EOW上炎症未得到控制的患者,已升级为每周一次给药。

方法

2012年1月至2019年4月在西北大学进行的图表审查。

结果:在6和12个月每周一次ADA的治疗成功次数。

结果

25名患者中有14名(56%)在6个月时达到了疾病控制;在12个月内没有发生其他故障。

结论

对于标准剂量的顽固性炎症患者,每周ADA是合理的治疗选择。

更新日期:2020-04-17
down
wechat
bug